Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).

Chiari R, Ricciuti B, Landi L, Morelli AM, Delmonte A, Spitaleri G, Cortinovis DL, Lamberti G, Facchinetti F, Pilotto S, Verusio C, Chella A, Bonanno L, Galetta D, Cappuzzo F.

Clin Lung Cancer. 2019 Jun 18. pii: S1525-7304(19)30154-8. doi: 10.1016/j.cllc.2019.06.012. [Epub ahead of print]

PMID:
31607443
2.

Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer.

De Matteis S, Canale M, Verlicchi A, Bronte G, Delmonte A, Crinò L, Martinelli G, Ulivi P.

J Oncol. 2019 Aug 19;2019:7475364. doi: 10.1155/2019/7475364. eCollection 2019. Review.

3.

Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial.

Landi L, Chiari R, Tiseo M, D'Incà F, Dazzi C, Chella A, Delmonte A, Bonanno L, Giannarelli D, Cortinovis DL, De Marinis F, Borra G, Morabito A, Gridelli C, Galetta D, Barbieri F, Grossi F, Capelletto E, Minuti G, Mazzoni F, Verusio C, Bria E, Alì G, Bruno R, Proietti A, Fontanini G, Crinò L, Cappuzzo F.

Clin Cancer Res. 2019 Aug 15. pii: clincanres.0994.2019. doi: 10.1158/1078-0432.CCR-19-0994. [Epub ahead of print]

PMID:
31416808
4.

Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases.

Cortinovis D, Chiari R, Catino A, Grossi F, DE Marinis F, Sperandi F, Piantedosi F, Vitali M, Parra HJS, Migliorino MR, Tondini C, Tassinari D, Frassoldati A, Verderame F, Pazzola A, Cognetti F, Palmiotti G, Marchetti P, Santoro A, Giannarelli D, Colonese F, Delmonte A.

Anticancer Res. 2019 Aug;39(8):4265-4271. doi: 10.21873/anticanres.13590.

PMID:
31366516
5.

Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial.

Capelletto E, Migliorino MR, Morabito A, Chiari R, Grossi F, Tiseo M, Costanzo FD, Delmonte A, Romano G, Galetta D, Scotti V, Gregorc V, Pisconti S, Ceresoli GL, Del Conte A, Ciuffreda L, Colantonio I, Bria E, Ricciardi S, Manzo A, Metro G, Morelli AM, Critelli R, Pacchiana MV, Stura I, Migliaretti G, Novello S.

Lung Cancer. 2019 Aug;134:210-217. doi: 10.1016/j.lungcan.2019.06.028. Epub 2019 Jun 27.

PMID:
31319983
6.

Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM).

Facchinetti F, Pilotto S, Metro G, Baldini E, Bertolaccini L, Cappuzzo F, Delmonte A, Gasparini S, Inno A, Marchetti A, Passiglia F, Puma F, Ricardi U, Rossi A, Crinò L, Novello S.

Tumori. 2019 Jul;105(5_suppl):3-14. doi: 10.1177/0300891619857418.

PMID:
31264531
7.

Biometric and morphological features of the fetal bladder in lower urinary tract obstruction on magnetic resonance imaging: new perspectives for fetal cystoscopy.

Vinit N, Grevent D, Millischer-Bellaiche AE, Pandya VM, Sonigo P, Delmonte A, Sarnacki S, Aigrain Y, Boddaert N, Bessières B, Benchimol G, Salomon LJ, Stirnemann JJ, Blanc T, Ville Y.

Ultrasound Obstet Gynecol. 2019 Apr 22. doi: 10.1002/uog.20297. [Epub ahead of print]

PMID:
31006924
8.

Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.

Crinò L, Bidoli P, Delmonte A, Grossi F, De Marinis F, Ardizzoni A, Vitiello F, Lo Russo G, Parra HS, Cortesi E, Cappuzzo F, Calabrò L, Tiseo M, Turci D, Gamucci T, Antonelli P, Morabito A, Chella A, Giannarelli D, Galetta D.

Oncologist. 2019 Apr 17. pii: theoncologist.2018-0737. doi: 10.1634/theoncologist.2018-0737. [Epub ahead of print]

PMID:
30996007
9.

Targeting RET-rearranged non-small-cell lung cancer: future prospects.

Bronte G, Ulivi P, Verlicchi A, Cravero P, Delmonte A, Crinò L.

Lung Cancer (Auckl). 2019 Mar 20;10:27-36. doi: 10.2147/LCTT.S192830. eCollection 2019. Review.

10.

Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.

Crinò L, Bronte G, Bidoli P, Cravero P, Minenza E, Cortesi E, Garassino MC, Proto C, Cappuzzo F, Grossi F, Tonini G, Sarobba MG, Pinotti G, Numico G, Samaritani R, Ciuffreda L, Frassoldati A, Bregni M, Santo A, Piantedosi F, Illiano A, De Marinis F, Tamberi S, Giannarelli D, Delmonte A.

Lung Cancer. 2019 Mar;129:35-40. doi: 10.1016/j.lungcan.2018.12.025. Epub 2019 Jan 15.

PMID:
30797489
11.

BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience.

Rihawi K, Giannarelli D, Galetta D, Delmonte A, Giavarra M, Turci D, Garassino M, Tiseo M, Barbieri F, Panni S, Ardizzoni A.

J Thorac Oncol. 2019 Mar;14(3):e57-e59. doi: 10.1016/j.jtho.2018.11.036. No abstract available.

PMID:
30782386
12.

Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer.

Ulivi P, Petracci E, Marisi G, Baglivo S, Chiari R, Billi M, Canale M, Pasini L, Racanicchi S, Vagheggini A, Delmonte A, Mariotti M, Ludovini V, Bonafè M, Crinò L, Grignani F.

J Clin Med. 2019 Jan 23;8(2). pii: E131. doi: 10.3390/jcm8020131.

13.

EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer.

John T, Akamatsu H, Delmonte A, Su WC, Lee JS, Chang GC, Huang X, Jenkins S, Wu YL.

Lung Cancer. 2018 Dec;126:133-138. doi: 10.1016/j.lungcan.2018.10.027. Epub 2018 Nov 1.

PMID:
30527177
14.

Direct Lewis Acid Catalyzed Conversion of Enantioenriched N-Acyloxazolidinones to Chiral Esters, Amides, and Acids.

Stevens JM, Parra-Rivera AC, Dixon DD, Beutner GL, DelMonte AJ, Frantz DE, Janey JM, Paulson J, Talley MR.

J Org Chem. 2018 Dec 7;83(23):14245-14261. doi: 10.1021/acs.joc.8b02451. Epub 2018 Nov 19.

PMID:
30412670
15.

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations.

Passiglia F, Cappuzzo F, Alabiso O, Bettini AC, Bidoli P, Chiari R, Defferrari C, Delmonte A, Finocchiaro G, Francini G, Gelsomino F, Giannarelli D, Giordano M, Illiano A, Livi L, Martelli O, Natoli C, Puppo G, Ricevuto E, Roca E, Turci D, Galetta D.

Br J Cancer. 2019 Jan;120(1):57-62. doi: 10.1038/s41416-018-0234-3. Epub 2018 Oct 31.

PMID:
30377342
16.

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.

Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S.

N Engl J Med. 2018 Nov 22;379(21):2027-2039. doi: 10.1056/NEJMoa1810171. Epub 2018 Sep 25.

17.

Frequency of actionable alterations in epidermal growth factor receptor (EGFR) wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR).

Chiadini E, Canale M, Delmonte A, Dazzi C, Casanova C, Capelli L, Mariotti M, Papi M, Gamboni A, Puccetti M, Bravaccini S, Dubini A, Calistri D, Crinò L, Ulivi P.

J Thorac Dis. 2018 Aug;10(8):4858-4864. doi: 10.21037/jtd.2018.07.22.

18.

Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.

Grossi F, Crinò L, Logroscino A, Canova S, Delmonte A, Melotti B, Proto C, Gelibter A, Cappuzzo F, Turci D, Gamucci T, Antonelli P, Marchetti P, Santoro A, Giusti S, Di Costanzo F, Giustini L, Del Conte A, Livi L, Giannarelli D, de Marinis F.

Eur J Cancer. 2018 Sep;100:126-134. doi: 10.1016/j.ejca.2018.05.015. Epub 2018 Jul 13.

PMID:
30014881
19.

Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer.

Bronte G, Bravaccini S, Bronte E, Burgio MA, Rolfo C, Delmonte A, Crinò L.

Biol Rev Camb Philos Soc. 2018 Nov;93(4):1735-1746. doi: 10.1111/brv.12416. Epub 2018 Apr 19. Review.

PMID:
29671943
20.

Perspectives in small cell lung cancer: is something moving?

Crinò L, Delmonte A.

Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S47-S50. doi: 10.21037/tlcr.2017.10.12. No abstract available.

21.

Bordetella bronchiseptica pneumonia in a patient with lung cancer; a case report of a rare infection.

Monti M, Diano D, Allegrini F, Delmonte A, Fausti V, Cravero P, Marcantognini G, Frassineti GL.

BMC Infect Dis. 2017 Sep 25;17(1):644. doi: 10.1186/s12879-017-2736-7.

22.

Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.

Gobbini E, Galetta D, Tiseo M, Graziano P, Rossi A, Bria E, Di Maio M, Rossi G, Gregorc V, Riccardi F, Scotti V, Ceribelli A, Buffoni L, Delmonte A, Franchina T, Migliorino MR, Cortinovis D, Pisconti S, Bordi P, Catino A, Maiello E, Arizio F, Novello S; other Co-Authors.

Lung Cancer. 2017 Sep;111:30-37. doi: 10.1016/j.lungcan.2017.06.009. Epub 2017 Jun 16.

PMID:
28838394
23.

Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.

Bonelli MA, Digiacomo G, Fumarola C, Alfieri R, Quaini F, Falco A, Madeddu D, La Monica S, Cretella D, Ravelli A, Ulivi P, Tebaldi M, Calistri D, Delmonte A, Ampollini L, Carbognani P, Tiseo M, Cavazzoni A, Petronini PG.

Neoplasia. 2017 Aug;19(8):637-648. doi: 10.1016/j.neo.2017.05.003. Epub 2017 Jul 11.

24.

Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.

Canale M, Petracci E, Delmonte A, Chiadini E, Dazzi C, Papi M, Capelli L, Casanova C, De Luigi N, Mariotti M, Gamboni A, Chiari R, Bennati C, Calistri D, Ludovini V, Crinò L, Amadori D, Ulivi P.

Clin Cancer Res. 2017 May 1;23(9):2195-2202. doi: 10.1158/1078-0432.CCR-16-0966. Epub 2016 Oct 25.

25.

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.

Casadei Gardini A, Chiadini E, Faloppi L, Marisi G, Delmonte A, Scartozzi M, Loretelli C, Lucchesi A, Oboldi D, Dubini A, Frassineti GL, Ulivi P.

BMC Cancer. 2016 Jul 7;16:429. doi: 10.1186/s12885-016-2463-2.

26.

Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.

Ulivi P, Chiadini E, Dazzi C, Dubini A, Costantini M, Medri L, Puccetti M, Capelli L, Calistri D, Verlicchi A, Gamboni A, Papi M, Mariotti M, De Luigi N, Scarpi E, Bravaccini S, Turolla GM, Amadori D, Crinò L, Delmonte A.

Clin Lung Cancer. 2016 Sep;17(5):384-390. doi: 10.1016/j.cllc.2015.11.004. Epub 2015 Dec 1.

PMID:
26712101
27.

Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis.

Chiari R, Metro G, Iacono D, Bellezza G, Rebonato A, Dubini A, Sperduti I, Bennati C, Paglialunga L, Burgio MA, Baglivo S, Giusti R, Minotti V, Delmonte A, Crinò L.

Lung Cancer. 2015 Nov;90(2):255-60. doi: 10.1016/j.lungcan.2015.09.009. Epub 2015 Sep 14.

PMID:
26395848
28.

Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results.

Pasini A, Delmonte A, Tesei A, Calistri D, Giordano E.

Drugs. 2015 Oct;75(15):1757-71. doi: 10.1007/s40265-015-0461-3. Review.

PMID:
26347133
29.

Molecular features and clinical outcome of lung malignancies in very young people.

Catania C, Botteri E, Barberis M, Conforti F, Toffalorio F, De Marinis F, Boselli S, Noberasco C, Delmonte A, Spitaleri G, Spaggiari L, Rotmensz N, Passaro A, Bazolli B, Alfieri M, Manzotti M, Fumagalli C, Milani A, De Pas T.

Future Oncol. 2015;11(8):1211-21. doi: 10.2217/fon.15.10.

PMID:
25832878
30.

Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors.

Joerger M, Hess D, Delmonte A, Gallerani E, Barbieri P, Pace S, Sessa C.

Invest New Drugs. 2015 Apr;33(2):472-9. doi: 10.1007/s10637-015-0219-5. Epub 2015 Feb 20.

PMID:
25693886
31.

Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).

Joerger M, Hess D, Delmonte A, Gallerani E, Fasolo A, Gianni L, Cresta S, Barbieri P, Pace S, Sessa C.

Br J Clin Pharmacol. 2015 Jul;80(1):128-38. doi: 10.1111/bcp.12583. Epub 2015 Jun 3.

32.

Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?

Ulivi P, Delmonte A, Chiadini E, Calistri D, Papi M, Mariotti M, Verlicchi A, Ragazzini A, Capelli L, Gamboni A, Puccetti M, Dubini A, Burgio MA, Casanova C, Crinò L, Amadori D, Dazzi C.

Int J Mol Sci. 2014 Dec 31;16(1):747-57. doi: 10.3390/ijms16010747.

33.

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.

Soria JC, DeBraud F, Bahleda R, Adamo B, Andre F, Dienstmann R, Delmonte A, Cereda R, Isaacson J, Litten J, Allen A, Dubois F, Saba C, Robert R, D'Incalci M, Zucchetti M, Camboni MG, Tabernero J.

Ann Oncol. 2014 Nov;25(11):2244-51. doi: 10.1093/annonc/mdu390. Epub 2014 Sep 5. Erratum in: Ann Oncol. 2015 Feb;26(2):445. Dientsmann, R [corrected to Dienstmann, R].

PMID:
25193991
34.

Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.

Toffalorio F, Spitaleri G, Catania C, Dal Zotto L, Noberasco C, Delmonte A, Santarpia M, Vecchio F, Brunelli V, Rampinelli C, Barberis M, Fumagalli C, Zucchetti M, Zangarini M, Diena T, Danesi R, de Braud F, De Pas T.

Oncologist. 2014 Apr;19(4):344-5. doi: 10.1634/theoncologist.2013-0335. Epub 2014 Mar 27.

35.

Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options.

Lazzari C, Spitaleri G, Catania C, Barberis M, Noberasco C, Santarpia M, Delmonte A, Toffalorio F, Conforti F, De Pas TM.

Crit Rev Oncol Hematol. 2014 Mar;89(3):358-65. doi: 10.1016/j.critrevonc.2013.09.003. Epub 2013 Sep 26. Review.

PMID:
24156959
36.

The choice of whether to participate in a phase I clinical trial: increasing the awareness of patients with cancer. An exploratory study.

Catania C, Radice D, Spitaleri G, Adamoli L, Noberasco C, Delmonte A, Vecchio F, de Braud F, Toffalorio F, Goldhirsch A, De Pas T.

Psychooncology. 2014 Mar;23(3):322-9. doi: 10.1002/pon.3424. Epub 2013 Oct 10.

PMID:
24123459
37.

Breast phyllodes tumor: a review of literature and a single center retrospective series analysis.

Spitaleri G, Toesca A, Botteri E, Bottiglieri L, Rotmensz N, Boselli S, Sangalli C, Catania C, Toffalorio F, Noberasco C, Delmonte A, Luini A, Veronesi P, Colleoni M, Viale G, Zurrida S, Goldhirsch A, Veronesi U, De Pas T.

Crit Rev Oncol Hematol. 2013 Nov;88(2):427-36. doi: 10.1016/j.critrevonc.2013.06.005. Epub 2013 Jul 17. Review.

38.

Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors.

Sessa C, Lorusso P, Tolcher A, Farace F, Lassau N, Delmonte A, Braghetti A, Bahleda R, Cohen P, Hospitel M, Veyrat-Follet C, Soria JC.

Clin Cancer Res. 2013 Sep 1;19(17):4832-42. doi: 10.1158/1078-0432.CCR-13-0427. Epub 2013 Jul 5.

39.

EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung.

Conforti F, Catania C, Toffalorio F, Duca M, Spitaleri G, Barberis M, Noberasco C, Delmonte A, Santarpia M, Lazzari C, De Pas TM.

Lung Cancer. 2013 Sep;81(3):440-444. doi: 10.1016/j.lungcan.2013.05.019. Epub 2013 Jun 27.

PMID:
23810573
40.

A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.

Gallerani E, Zucchetti M, Brunelli D, Marangon E, Noberasco C, Hess D, Delmonte A, Martinelli G, Böhm S, Driessen C, De Braud F, Marsoni S, Cereda R, Sala F, D'Incalci M, Sessa C.

Eur J Cancer. 2013 Jan;49(2):290-6. doi: 10.1016/j.ejca.2012.09.009. Epub 2012 Oct 8. Review.

PMID:
23058787
41.

Safety of systemic chemotherapy in a patient with mitochondrial myopathy and non-small-cell lung cancer.

Catania C, Spitaleri G, Delmonte A, Giovannini M, Toffalorio F, Noberasco C, Bresolin N, Comi G, De Pas T.

J Clin Oncol. 2012 Aug 20;30(24):e226-8. doi: 10.1200/JCO.2011.40.1828. Epub 2012 Jun 18. No abstract available.

PMID:
22711848
42.

Features and prognostic factors of large node-negative non-small-cell lung cancers shifted to stage II.

Toffalorio F, Radice D, Spaggiari L, Sinno V, Barberis M, Spitaleri G, Giovannini M, Delmonte A, Catania C, Noberasco C, Brambilla D, de Braud F, Veronesi G, Solli P, De Pas T.

J Thorac Oncol. 2012 Jul;7(7):1124-30. doi: 10.1097/JTO.0b013e318252cfd4.

43.

Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials.

De Pas T, Giovannini M, Rescigno M, Catania C, Toffalorio F, Spitaleri G, Delmonte A, Barberis M, Spaggiari L, Solli P, Veronesi G, De Braud F.

Crit Rev Oncol Hematol. 2012 Sep;83(3):432-43. doi: 10.1016/j.critrevonc.2011.12.005. Epub 2012 Feb 25. Review.

PMID:
22366114
44.

Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma.

Poggi G, Montagna B, Melchiorre F, Quaretti P, Delmonte A, Riccardi A, Tagliaferri B, Sottotetti F, Di Cesare P, Stella MG, Villani L, Zorzetto M, Greco G, Cornalba G, Bernardo G.

Anticancer Res. 2011 Nov;31(11):3927-33.

PMID:
22110221
45.

Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.

De Pas T, Toffalorio F, Manzotti M, Fumagalli C, Spitaleri G, Catania C, Delmonte A, Giovannini M, Spaggiari L, de Braud F, Barberis M.

J Thorac Oncol. 2011 Nov;6(11):1895-901. doi: 10.1097/JTO.0b013e318227e8c6.

46.

Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination.

De Pas T, Rosati G, Spitaleri G, Boni C, Tucci A, Frustaci S, Scalamogna R, Radice D, Boselli S, Toffalorio F, Catania C, Noberasco C, Delmonte A, Vecchio F, de Braud F.

Chemotherapy. 2011;57(3):217-24. doi: 10.1159/000326466. Epub 2011 May 18.

PMID:
21597285
47.

Safety of concomitant administration of seasonal and/or H1N1 flu vaccination in patients receiving erlotinib for advanced non-small cell lung cancer.

Spitaleri G, Delmonte A, Toffalorio F, De Pas TM, Gregorc V.

J Thorac Oncol. 2010 May;5(5):752-4. doi: 10.1097/JTO.0b013e3181d6b8a1. No abstract available.

48.

Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1): structure-activity relationships leading to the identification of 6-((5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl)nicotinic acid (BMS-688521).

Watterson SH, Xiao Z, Dodd DS, Tortolani DR, Vaccaro W, Potin D, Launay M, Stetsko DK, Skala S, Davis PM, Lee D, Yang X, McIntyre KW, Balimane P, Patel K, Yang Z, Marathe P, Kadiyala P, Tebben AJ, Sheriff S, Chang CY, Ziemba T, Zhang H, Chen BC, DelMonte AJ, Aranibar N, McKinnon M, Barrish JC, Suchard SJ, Murali Dhar TG.

J Med Chem. 2010 May 13;53(9):3814-30. doi: 10.1021/jm100348u.

PMID:
20405922
49.

AVE8062: a new combretastatin derivative vascular disrupting agent.

Delmonte A, Sessa C.

Expert Opin Investig Drugs. 2009 Oct;18(10):1541-8. doi: 10.1517/13543780903213697. Review.

PMID:
19758109
50.

Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas.

Delmonte A, Ghielmini M, Sessa C.

Oncologist. 2009 May;14(5):511-25. doi: 10.1634/theoncologist.2008-0214. Epub 2009 May 1. Review.

Supplemental Content

Loading ...
Support Center